Latest Regulatory Approvals News

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

Cavalier Resources has completed and submitted all necessary mining approvals for the Crawford Gold Project, moving decisively toward production amid strong gold prices and ongoing funding talks.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Insurance Australia Group Limited (IAG) reported a 91.2% surge in net profit to $778 million for the half year ended December 2024, driven by robust insurance margins and higher investment income. The company also declared a 12-cent interim dividend, signaling confidence in its financial outlook.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Beacon Minerals has secured key regulatory approvals to launch multiple drilling programs at its Lady Ida Iguana Project, setting the stage for intensified exploration activity over the coming months.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

Osteopore Limited has announced a $20 million convertible notes offering aimed at bolstering its capital for ongoing operations and future projects. The highly speculative offer targets sophisticated investors and underscores the company’s strategic funding approach amid competitive medical device markets.